A drug previously developed by Novartis and picked up by co-development partner Dainippon Sumitomo Pharma is showing promise as a fast-acting and safer treatment for anxiety, German researchers reported. The compound, labeled XBD173, affects the brain chemical GABA differently from Valium and other anxiety pills in such a way that it promotes the synthesis of neurosteroids that modulate the effects of GABA.

Full Story:

Related Summaries